Skin Microbial Ecology in Atopic Dermatitis

Part of paid clinical trials in Rochester, New York.

Sponsor
University of Rochester
Study ID
NCT04170244
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
13 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • AD subject visit sampling procedures — OTHER
    Skin swabs for microbial analysis, Tape stripping and transepidermal water loss measurements (TEWL) with tape stripping (all patients) to assess skin barrier function, blood serum (adults \& optional for adolescents), and optional biopsy (adults only)
  • PS subject visit sampling procedures — OTHER
    Skin swabs for microbial analysis, Tape stripping and transepidermal water loss measurements (TEWL) with tape stripping (all patients) to assess skin barrier function, and blood serum (optional for all PS subjects)
  • Healthy control visit sampling procedures — OTHER
    Skin swabs for microbial analysis, Tape stripping and transepidermal water loss measurements (TEWL) with tape stripping (all patients) to assess skin barrier function, blood serum (adults \& optional for adolescents), and optional biopsy (adults only)

Study Details

Everybody's skin has bacteria that normally lives on it. Previous research has shown that people with eczema (or atopic dermatitis \[AD\]) have much higher concentrations of a certain bacteria (S. aureus), especially when their disease is active but little is known about the role that this bacteria plays in psoriasis (i.e. disease severity, biomarkers and skin barrier function). The overarching purpose of this longitudinal study is to understand how the abundance of skin S. aureus (and several commensal bacteria) change as a consequence of standard of care treatment in the URMC dermatology clinics. Other assays and biospecimens will also be collected to address a number of questions.

Key Dates

Start date
Apr 17, 2019
Status verified
May 2025
Primary completion
Mar 1, 2027
Completion
Apr 1, 2027

Study Design

Enrollment
240 participants (estimated)

Arms

  • Arm: Atopic Dermatitis
    Intervention is whatever Rx the URMC dermatologist thinks is best suited to the subject as part of "real-world" disease management in her clinic. 1\. Ages: 1. 13-65 yrs of age (inclusive), all genders, races and ethnicities 2. Additional 66+ yrs of age group, all genders, races and ethnicities
  • Arm: Healthy control
    No intervention Ages: 1. 13-65 yrs of age (inclusive), all genders, races and ethnicities 2. Additional 66+ yrs of age group, all genders, races and ethnicities
  • Arm: Psoriasis
    Intervention is whatever Rx the URMC dermatologist thinks is best suited to the subject as part of "real-world" disease management in her clinic. Ages:13-65 yrs of age (inclusive), all genders, races and ethnicities.

Primary Outcome Measure

Abundance of colony forming units (rCFU/cm^2, and CFU/rCFU) of Staphylococcus aureus (S. aureus) [ Time Frame: year 1-7 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Rochester Medical CenterRochesterNew York14642
Lisa Beck, MD
[email protected]
585-275-7546

Find similar trials in Rochester, NY

By condition
Atopic dermatitis / eczemaPsoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
University of Rochester Medical Center· Rochester, NY

Related Studies